The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > TRENDS
TRENDS
-
“Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
-
Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
-
AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
-
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
-
Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
-
Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
-
IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
“80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
-
Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
-
Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
March 27, 2015
-
Most Global Products on Track to Clear Their FY2014 Sales Forecasts; Abilify Posting Sales of 650 Billion Yen
March 16, 2015
-
Will SGLT-2 Inhibitors Catch On? Breakout Will Require Accumulation of Data
February 25, 2015
-
Chugai Aims to Surpass 200 Billion Yen in Its Domestic Oncology Sales in 2015
February 13, 2015
-
EFPIA Predicts Growth in Ethical Drug Market to Just 10 Trillion Yen in 2025
February 6, 2015
-
Edoxaban Approved in US with Restriction on Use; Impact on Daiichi Sankyo’s Midterm Business Plan Remains Unclear
January 30, 2015
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…